RxDoctor Payments Data

Shawn Kelly

Interventional Cardiology · Great Falls, MTNPI 1932425329

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Edwards Lifesciences at 57.9% of the total. Reporting peaked in 2022 at $2,306 and has fallen 64.2% since, to $825 in 2023. That places this record below the midpoint for interventional cardiology clinicians in MT, where the typical reported total is $5,910.

$5,562in general payments, 2019–2025

Across 144 payments — averaging $38.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • E.r. Squibb & Sons, L.L.C.$375
  • Actelion Pharmaceuticals US, Inc.$337
  • Novartis$331
  • Merck$206
  • Johnson & Johnson$163
  • plus $929 from 20 others

What the payments were for

  • Travel & lodging$2,54646%
  • Food & beverage$2,91552%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,562 in reported general payments places this provider in the 45th percentile of 22 interventional cardiology providers in Montana.

See all interventional cardiology providers in Montana

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$41,333
BrilintaTicagrelor11$10,384
Atorvastatin Calcium77$1,142
Rosuvastatin Calcium64$949
Metoprolol Succinate58$898
ClopidogrelClopidogrel Bisulfate71$774
Ezetimibe26$483
Losartan Potassium40$407
Isosorbide Mononitrate ErIsosorbide Mononitrate50$390
Amiodarone Hcl12$346
Valsartan14$255
Bisoprolol Fumarate15$243
Metoprolol Tartrate32$226
Pravastatin Sodium11$171
Carvedilol24$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$41,33344 claims
AstraZenecaBrilinta$125$10,38411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 22 interventional cardiology providers in Montana.

Other interventional cardiology in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →